In Australia, many peptide therapies are not approved by the Therapeutic Goods Administration (TGA), and their safety and efficacy have not been fully established in large-scale human trials (Therapeutic Goods Administration [TGA], 2023)
Subcutaneous injections deliver consistently, can be administered on the patients schedule, and dont require a clinic visit each time
Moreover, the continuous release of ROS and lipid peroxidation unfavourable influences cerebral blood flow, leading to immunosuppression and brain plasticity (Shohami and Kohen, 2011)
This approach has shown improved penetration in research settings
We would enjoy that
Combined GHRH + GHRP/ghrelinmimetic administration produces synergistic, amplified GH pulses compared to either agent alone [1] [2]